# Helena A. Yu

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/helena-a-yu/

## Facts

| Field | Value |
| --- | --- |
| Citations | 17,705 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 59 |
| i10-index | 153 |
| Last Known Institution | Memorial Sloan Kettering Cancer Center |
| OpenAlex ID | https://openalex.org/A5014837967 |
| ORCID iD | 0000-0002-0377-9510 |
| Works | 651 |

## Researcher papers

Showing 12 of 18.

- [Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with <i>EGFR</i> -Mutant Lung Cancers](https://scholariq.org/papers/analysis-of-tumor-specimens-at-the-time-of-acquired-resistance-to-egfr-tki/)
- [Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies](https://scholariq.org/papers/prospective-comprehensive-molecular-characterization-of-lung-adenocarcinomas-for/)
- [Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring <i>MET</i> Mutations Causing Exon 14 Skipping](https://scholariq.org/papers/response-to-met-inhibitors-in-patients-with-stage-iv-lung-adenocarcinomas/)
- [Lineage plasticity in cancer: a shared pathway of therapeutic resistance](https://scholariq.org/papers/lineage-plasticity-in-cancer-a-shared-pathway-of-therapeutic-resistance/)
- [<i>EGFR</i> -Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes](https://scholariq.org/papers/i-egfr-i-mutant-adenocarcinomas-that-transform-to-small-cell-lung-cancer-and/)
- [Effects of Co-occurring Genomic Alterations on Outcomes in Patients with <i>KRAS</i> -Mutant Non–Small Cell Lung Cancer](https://scholariq.org/papers/effects-of-co-occurring-genomic-alterations-on-outcomes-in-patients-with-i-kras/)
- [Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes](https://scholariq.org/papers/concurrent-rb1-and-tp53-alterations-define-a-subset-of-egfr-mutant-lung-cancers/)
- [TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer](https://scholariq.org/papers/tatton-a-multi-arm-phase-ib-trial-of-osimertinib-combined-with-selumetinib/)
- [Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib](https://scholariq.org/papers/severe-immune-related-adverse-events-are-common-with-sequential-pd-l-1-blockade/)
- [Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study](https://scholariq.org/papers/osimertinib-plus-savolitinib-in-patients-with-egfr-mutation-positive-met/)
- [EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer](https://scholariq.org/papers/egfr-mutation-subtypes-and-response-to-immune-checkpoint-blockade-treatment-in/)
- [HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> Amplified or Mutant Lung Cancers](https://scholariq.org/papers/her2-mediated-internalization-of-cytotoxic-agents-in-i-erbb2-i-amplified-or/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Memorial Sloan Kettering Cancer Center](https://scholariq.org/institutions/memorial-sloan-kettering-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.